ImmunoGen (IMGN) Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMGN shares.
View IMGN analyst ratings or view top-rated stocks.

7 analysts have issued 1 year target prices for ImmunoGen's shares. Their IMGN share price forecasts range from $16.00 to $27.00. On average, they anticipate the company's stock price to reach $22.88 in the next twelve months. This suggests a possible upside of 44.1% from the stock's current price.
View analysts price targets for IMGN or view top-rated stocks among Wall Street analysts.

ImmunoGen's stock was trading at $4.96 at the beginning of the year. Since then, IMGN stock has increased by 220.0% and is now trading at $15.87.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, November 3rd 2023.
View our IMGN earnings forecast.

ImmunoGen, Inc. (NASDAQ:IMGN) released its earnings results on Monday, July, 31st. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.14. The biotechnology company earned $83.20 million during the quarter, compared to analyst estimates of $49.15 million. ImmunoGen had a negative net margin of 96.02% and a negative trailing twelve-month return on equity of 76.92%. The firm's revenue for the quarter was up 485.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.24) earnings per share.

ETFs with the largest weight of ImmunoGen (NASDAQ:IMGN) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Products ETF (BBP), Range Cancer Therapeutics ETF (CNCR), iShares Micro-Cap ETF (IWC), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Future Gen 200 ETF (QQQS), Invesco DWA SmallCap Momentum ETF (DWAS) and iShares Biotechnology ETF (IBB).

ImmunoGen updated its FY 2023 earnings guidance on Monday, July, 31st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $45.00 million-$50.00 million.

16 employees have rated ImmunoGen Chief Executive Officer Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX).

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

Shares of IMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IMGN stock can currently be purchased for approximately $15.87.

ImmunoGen (NASDAQ:IMGN) has a market capitalization of $3.95 billion and generates $108.78 million in revenue each year. The biotechnology company earns $-222,930,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis.

The company employs 277 workers across the globe.

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The official website for the company is www.immunogen.com. The biotechnology company can be reached via phone at (781) 895-0600, via email at courtney.okonek@immunogen.com, or via fax at 781-895-0611.